Cadavid Diego 4
4 · Fulcrum Therapeutics, Inc. · Filed Jun 4, 2020
Insider Transaction Report
Form 4
Cadavid Diego
See Remarks
Transactions
- Sale
Common Stock
2020-06-02$20.00/sh−45$900→ 66,785 total - Sale
Common Stock
2020-06-03$20.18/sh−338$6,820→ 66,785 total - Exercise/Conversion
Stock Option (right to buy)
2020-06-03−338→ 14,814 totalExercise: $4.83Exp: 2028-07-10→ Common Stock (338 underlying) - Exercise/Conversion
Common Stock
2020-06-02$4.83/sh+45$217→ 66,830 total - Exercise/Conversion
Common Stock
2020-06-03$4.83/sh+338$1,633→ 67,123 total - Exercise/Conversion
Stock Option (right to buy)
2020-06-02−45→ 15,152 totalExercise: $4.83Exp: 2028-07-10→ Common Stock (45 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.